Metilfenidat kullanımı sonrası trombositopeni gelişen bir ergen olguda atomoksetine güvenli bir geçiş: Olgu sunumu

Metilfenidat, dikkat eksikliği hiperaktivite bozukluğu tedavisinde sık kullanılan etkili ve güvenilir bir ajandır. Trombositopeni kandaki trombosit sayısının 150.000/mm3 ’ten az olmasıdır. Trombositopeni, asemptomatik gidişten kafa içi kanamalar gibi ciddi komplikasyonlara neden olabilen önemli bir hematolojik sorundur. Trombositopenin ilaç kullanımı da dahil olmak üzere birçok nedene bağlı olarak gelişebildiği bilinmektedir. Metilfenidat kullanımı sırasında trombositopeni gelişimi ile ilgili az sayıda olgu bildirimi vardır ve bildiğimiz kadarıyla bu yan etkinin yönetilmesi ile ilgili herhangi bir olgu bildirimine rastlanmamıştır. Bu yazıda, DEHB’li bir ergen olguda olasılıkla metilfenidat kullanmaya bağlı trombositopeni gelişimi ve bu durumun atomoksetine güvenli bir geçiş yapılarak başarılı bir şekilde yönetilmesi sunulmuştur. (Anadolu Psikiyatri Derg 2020; 21(5):557-560)

Successful management of methylphenidate related thrombocytopenia during ADHD treatment: a case report

Methylphenidate is an effective and well tolerated agent frequently used in the treatment of attention deficit hyperactivity disorder. Thrombocytopenia is defined as a blood platelet count less than 150,000/mm3, and is an importanthematological side-effect capable of causing mild symptoms or severe complications such as intracranial hemorrhage. Thrombocytopenia may develop in association with various causes, including drug use. There have beenvery few case reports of thrombocytopenia developing during methylphenidate use, and to the best of our knowledge there have been no reports concerning the management of this side-effect. This report describes the development of thrombocytopenia likely related to methylphenidate therapy in an adolescent with attention deficit hyperactivity disorder and successful management with a safety switch to atomoxetine. (Anatolian Journal of Psychiatry 2020; 21(5):557-560)

PDF

___

1. Green WH. Sympathomimetic amines and central nervous system stimulants. Child and Adolescent Clinical Psychopharmacology, fourth ed., Lippincott: Williams & Wilkins, 2007, pp.55-90.
2. Coskun M, Adak I, Akaltun I. Bilateral gynecomastia in a preadolescent boy while under treatment with methylphenidate and paroxetine. J Clin Psychopharmacol 2014; 34(4):537-538. 3. Gauer RL, Braun MM. Thrombocytopenia. Am Fam Physician 2012; 85(6):612-622. 4. Coskun, M, Adak I. Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder. J Clin Psychopharmacol 2017; 37(5):637- 639.
5. Avcil S. Nasal bleeding probably associated with methylphenidate. J Child Adolesc Psychopharmacol 2017; 27(10):924-925.
6. Ercan ES, Inci SB, Ipci M. Is there an effect of methyl-phenidate on thrombocytopenia? J Clin Psychopharmacol 2017; 37(3):374.
7. Grossman LK, Grossman NJ. Methylphenidate and idiopathic thrombocytopenic purpura--is there an association? J Fam Pract 1985; 20(3):302-304. 8. Kuperman, AA, Yaniv I, Stahl B, Tamary H. Methylphenidate as a possible cause of thrombocytepenia. Ann Pharmacother 2003; 37(7-8): 1146-1146.
9. Nieminen U, Kekomäki R. Quinidine‐induced thrombocytopenic purpura: clinical presentation in relation to drug-dependent and drug‐independent platelet antibodies. Br J Haematol 1992; 80(1):77- 82.
10. Veneri D, Franchini M, Randon F, Nichele I, Pizzolo G, Ambrosetti A. Thrombocytopenias: a clinical point of view. Blood Transfusion 2009; 7(2):75.
11. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006; 4(11):2377-2383.
12. Naranjo CA, Busto U, Sellars EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2):239-245.
13. Danese E, Montagnana M, Favaloro EJ, Lippi G. Drug-Induced Thrombocytopenia: Mechanisms and Laboratory Diagnostics. In Seminars in Thrombosis and Hemostasis. Thieme Medical Publishers, 2019.
14. Weycker D, Hatfield M, Grossman A, Hanau A, Lonsh-teyn A, Sharma A, Chandler D. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer 2019; 19(1):151.
15. George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. ASH Education Program Book, 2009(1): 153-158.
16. Warrer P, Thomsen PH, Dalsgaard S, Hansen EH, Aagaard L, Wallach Kildemoes H, et al. Switch in therapy from methylphenidate to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: an analysis of patient records. J Child Adolesc Psychopharmacol 2016; 26(4):354-361